Glenmark Pharmaceuticals Limited has had a difficult run in the US in the fiscal first quarter though the firm expects things to steady hereon as new launches kick in, including the anticipated debut of Ryaltris (olopatadine hydrochloride/mometasone furoate nasal spray) “anytime now”.
At the earnings call for the fiscal first quarter ended 30 June 2022, Glenmark’s leadership echoed what some peers have...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

